Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07463599) titled 'Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: HonorHealth Research Institute
Condition:
Metastatic Colorectal Carcinoma (mCRC)
Colorectal Cancer (CRC)
Adenomatous Polyposis Coli (APC) Gene Mutation
Catenin Beta-1 (CTNNB1) Gene Mutation
Intervention:
Drug: Tegavivint
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: February 17, 2026
Target Sam...